The Ricordi Chamber – a “bold new approach” in diabetes research marks 40 years since discovery

In the mid-1980s, when isolating insulin-producing cells from the human pancreas seemed nearly impossible, Dr Camillo Ricordi introduced a bold new approach – one that transformed fragile experimentation into a reliable, life-changing science.

Dr Ricordi, later based at the Diabetes Research Institute in Miami, was hailed for the discovery of what is now regarded at the “gold standard in islet isolation”.

The Ricordi Chamber has since powered thousands of scientific discoveries, enabling clinical transplantation, and helping to bring the field closer than ever to restoring the body’s natural ability to produce insulin.

The Diabetes Research Institute works on cure-focused diabetes research, with the aim to develop a biological cure for diabetes by restoring natural insulin production and normalising blood glucose levels without imposing other risks.

The Diabetes Research Institute said: “For millions of people living with diabetes, restoring the body’s natural ability to produce insulin once seemed unreachable. For decades, scientists faced a fundamental obstacle: insulin-producing beta cells – the very cells destroyed by diabetes – were extraordinarily difficult to isolate alive from the human pancreas. Early techniques were harsh, inefficient, and unreliable, slowing scientific progress and keeping life-changing therapies out of reach.

“That reality began to change 40 years ago with one bold idea.”

The roots of the discovery could be traced back even further, to the first report of islet isolation, published in 1964.

This described the painstaking process of micro-dissecting islets one by one. Over the next two decades, isolating insulin-producing islet cells remained extremely difficult and often damaging.

While this report garnered growing scientific interest, progress remained slow. Researchers needed a fundamentally different approach.

Although promising, the University of Milan lacked the resources needed for development.

In order to move forward with his vision, Dr Ricordi relocated to Washington University in St. Louis to work with islet transplant pioneer Dr Paul E. Lacy.

Initial skepticism delayed progress while Ricordi refined his approach using pre-clinical models – until a fateful breakthrough night of discovery.

The Diabetes Research Institute said: “One Friday evening, a poor-quality donor pancreas – deemed unsuitable for research – arrived in Dr Lacy’s laboratory. After the lab cleared out, Ricordi retrieved the discarded organ and tested his method overnight.

“When morning came, the microscope revealed what had long seemed impossible: healthy, viable insulin-producing islets isolated in unprecedented numbers.

“The Ricordi Chamber was no longer a concept – it was a breakthrough.”

A patent application was filed in June 1987, and in 1988 the first scientific paper describing the method was published in the Diabetes journal.

The publication introduced a revolutionary continuous processing system that minimised tissue damage while dramatically improving islet yield and quality.

The Diabetes Research Institute said: “The invention soon became known worldwide as the Ricordi Chamber, later recognised as the gold standard in human islet isolation and adopted by research and transplant centres across the globe.”

The innovative new method turned into a clinical reality on 10th January 1990, when, purified human islets isolated using the Ricordi Chamber were infused into the liver of a 15-year-old patient – effectively engineering a “hepato-pancreas.”

Following the intrahepatic islet infusion in this initial series, several patients achieved prolonged insulin independence.

The results were published in The Lancet on 18th August 1990, marking a defining moment in the history of diabetes treatment.

In 1993, Dr Ricordi was recruited to the Diabetes Research Institute at the University of Miami, where he led the Cell Transplant Center and later the entire institute for three decades.

The Ricordi Chamber enabled the Diabetes Research Institute and its collaborators worldwide to refine protocols, improve patient outcomes, and establish the scientific foundation for modern islet transplantation.